Top Biopharma Deal June 2021: iTeos – GSK for EOS-448 anti-TIGIT mAb for Solid Tumors
Top Biopharma Partnership by Upfront Cash and Equity
June 2021
iTeos development and commercialization deal with GSK for EOS-448
Announced: June 14, 2021
Total Deal Value: $2,075M
Upfront Cash: $625M
Upfront Equity: n/a
Option Payments: n/a
Milestones: $1,450M Dev. and Sales
Cost and Profit Split: 50% U.S.
Royalties: Tiered ex-U.S.
The Asset:
Phase II EOD-448 anti-TIGIT IgG1 mAb which binds to TIGIT and blocks its interaction with certain ligands, including CD155, CD112, and CD226 to activate an immune response from T cells and natural killer cells as part of the checkpoint pathway. IgG1 binds FcyR and triggers a pro-inflammatory cytokine release and activates antigen presenting cells and depletion of TIGIT+ Tregs and exhausted T cells.
Deal Structure:
Development and Commercial License
Partnership Features:
GSK is fully responsible for R&D costs, 50% of U.S. commercialization, and 100% of ex-U.S. commercialization.
The Details:
- iTeos granted GSK exclusive, worldwide rights to develop and commercialize EOS-448 for solid tumors.
- GSK will be fully responsible for global R&D costs, 50% of U.S. commercialization, and 100% of ex-U.S. commercialization costs.
- iTeos Therapeutics will receive $625M up front and is eligible to receive up to $1.45B in milestone payments, a 50% cost and profit split in the U.S., and tiered royalties ex-U.S.
Last Month:
The Deal of the Month for May 2021 was also a TIGIT deal among Agenus and BMS for AGEN-1777. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
25,544
Deal Profiles
15,147
Funding Rounds
28,034
Company Profiles
17,936
Product Profiles
119K+
Clinical Trials
3,982
Business Developers
Specifically for Biotech, Pharma, Device, and Diagnostics
Get more done.
Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.
More Research by DealForma
Biotech and Pharma Deals in 2020
Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was up 23 percent over 2019 and total deal values rose 31 percent from the previous year, driven in part by advances in technological and molecular understandings of disease pathways, and a drive toward targeted precision medicines.
Biopharma Deal of the Month: Vir – GSK for VIR-2482 and mAbs for Influenza
Vir Biotechnology and GSK expanded their partnership with a new deal to develop VIR-2482 and mAbs for influenza. This was the largest upfront cash and equity for a partnership signed in Feb. 2021.
Biotech and Pharma M&A in 2020
Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.
Life Sciences M&A Tops $240 Billion in 2019
This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...
Cancer Cell Therapy M&A
Over the last three years, there have been eight M&A deals for companies developing advanced first generation and next gen cancer cell therapies. Six of them have been completed to date.
Gene Therapy Deals, M&A, and Venture Funding
We looked at 10 years of gene therapy deals, M&A, venture funding, and academic partnerships for an article by John Carroll at Endpoints News.
Reverse Mergers in Biopharma
Biotech reverse mergers have been an alternate way for private biotechnology companies to gain a public listing. Here’s a quick table of over 10 years of deals.
Biopharma Partnering Sets Records in Q1 2019 after a Strong 2018
2019 biopharma dealmaking started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals.
Top 10 Venture Round Investors in Cancer Therapeutics
Celgene was among the top investors in cancer biotech companies. This is a look at the top 10 since 2010.
Life Sciences M&A Starts with a Bang in 2019 after Rebounding in 2018
Life Sciences M&A started with a bang in 2019 with one of the biggest deals to date – Bristol-Myers Squibb will acquire Celgene for $74 billion. We mined DealForma’s extensive database for historical M&A trends in biopharma, medical devices, and diagnostics to get an idea of what might lie ahead in 2019.
You met on Zoom. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.